TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03853044
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
Study: NCT03853044
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
Study: NCT05124717
Drug: Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of the Reference product was administered orallyn with 240 mL of water.
Study: NCT04749745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.
Study: NCT02135627
Drug: TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01211561
Drug: Selenium, selenomethionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive one 200 ug pill of Selenomethionine
Study: NCT01211561
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given one 200 ug placebo pill each day for 6 months
Study: NCT01926132
Drug: ascorbic acid 10g/20ml
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ascorbic acid 10g/20cc intravenous injection for 40mins
Study: NCT00399035
Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT00399035
Drug: XELOX (Capecitabine and Oxaliplatin)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15)
Study: NCT01500317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received placebo three times per day (tid) for 48 hours.
Study: NCT03419429
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.
Study: NCT00102661
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.
Study: NCT04357899
Drug: thrombolysis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04357899
Drug: initiation of antiplatelets, oral anticoagulation and lipid lowering drugs for secondary prevention
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00337038
Drug: N-acetylcystein(drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.O t.Siran 200mg x1 during one weak
Study: NCT01824290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
Study: NCT01824290
Drug: ERA as specific PAH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
Study: NCT03793686
Drug: PBCLN-003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT03793686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03341676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 0.9% w/v solution for injection
Study: NCT02710877
Drug: Sufentanil 4 mcg
Normalized name: sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil 0,4 mcg/ml through peridural catheter
Study: NCT02710877
Drug: Sufentanil 5 mcg
Normalized name: sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil 5 mcg through peridural catheter
Study: NCT00362895
Drug: Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in the study eye, single dose
Study: NCT00362895
Drug: Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in the study eye, single dose
Study: NCT05850143
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Multidose Prednisolone
Study: NCT03152123
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets over-capsuled
Study: NCT00109148
Drug: MK0364
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02742129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
Study: NCT03314935
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin at the protocol-defined dose and regimen.
Study: NCT04161690
Drug: Dexketoprofen Trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous dexketoprofen 50mg or intrathecal
Study: NCT01763437
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
Study: NCT02382354
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method
Study: NCT00646126
Drug: placebo tablet similar to active drug in shape and size
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage similar to active drug(standard three days regimen)
Study: NCT00688857
Drug: Diazoxide choline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily
Study: NCT00688857
Drug: Diazoxide choline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
Study: NCT01911455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02575144
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg PO twice daily on days 1-28 for a 28-day cycle
Study: NCT01298336
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg twice a day seven days a week
Study: NCT02406222
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT03092180
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
Study: NCT03864068
Drug: Inositol
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1gm/bid, 2gm/bid or 3gm/bid of Inositol powder
Study: NCT04021290
Drug: DTG/3TC FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.
Study: NCT00539578
Drug: MK0777
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 4 weeks
Study: NCT00539578
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 4 weeks
Study: NCT04351594
Drug: Biofreeze 4 % Topical Gel
Normalized name: Biofreeze 4 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofreeze gel with active manufactured ingredient (Menthol 4%)
Study: NCT01846702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as a SC injection.
Study: NCT01846702
Drug: LY3084077
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as a SC injection.
Study: NCT04841993
Drug: Cannabis oil
Normalized name: Cannabis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single administration of 15 drops (045 mL) of cannabis oil containing 1.8 mg THC and 3.8 mg CBD.
Study: NCT00444106
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00147576
Drug: CP-866,087
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01900665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02606630
Drug: ABT-555
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-555 will be administered on Visit 4 in Part 2 only
Study: NCT01039389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: bid placebo
Study: NCT01079312
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.
Study: NCT01079312
Drug: sedative mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)
Study: NCT01079312
Drug: remifentanil hydrochlorid
Normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)
Study: NCT02167321
Drug: Arm A : standard neoadjuvant chemoradiotherapy group
Approvals — FDA: no, EMA: no, PMDA: no
Description: radiation : 45Gy±5.4Gy/28Fx/5.5weeks concurrent chemoradiotherapy : 5-FU (400 mg/m2, IV bolus on D1-3, D29-31), leucovorin (20 mg/m2, IV bolus on D1-3, D29-31), preoperative capecitabine : 825 mg/m² p.o. twice daily during XRT, postoperative FL : 5-FU (400 mg/m2, IV bolus)+leucovorin (20m g/m2, IV bolus) on days 1-5 of each 28 day postoperative capecitabine : 1250 mg/m² p.o. twice daily on days 1-14 of each 21 day cycle FOLFOX : oxaliplatin 85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, leucovorin 200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, 5-FU 400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle
Study: NCT02167321
Drug: Arm B : adjuvant FOLFOX group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
Study: NCT01127620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: encapsulated tablets
Study: NCT00882024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, bid, 12 weeks
Study: NCT03381287
Drug: HTD1801 Tablets, 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day (250 mg BID)
Study: NCT03381287
Drug: HTD1801 Tablets, 1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day (500 mg BID)
Study: NCT03381287
Drug: HTD1801 Tablets, 2000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg/day (1000 mg BID)
Study: NCT03381287
Drug: Placebo to match 500 mg HTD1801
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets/day (1 tablet BID)
Study: NCT03381287
Drug: Placebo to match 1000 mg HTD1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets/day (2 tablet BID)
Study: NCT03381287
Drug: Placebo to match 2000 mg HTD1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 tablets/day (4 tablet BID)
Study: NCT00953706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02015780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasiglifam placebo-matching tablets
Study: NCT02015780
Drug: Antihyperglycemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
Study: NCT00000278
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01195428
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg daily
Study: NCT01195428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00660582
Drug: Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given in combination day 1 and 2, every second week, 8 cycles
Study: NCT00775255
Drug: clarithromycin 250 mg/5 mL powder for oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01101529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered instead of Emend
Study: NCT02175186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03672630
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500 MG Oral Tablet \[ZITHROMAX\]
Study: NCT02122380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo pill by mouth per day for 30 days
Study: NCT01783444
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)
Study: NCT02710539
Drug: perindopril, indapamide , amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
Study: NCT02710539
Drug: Tripliam (perindopril, indapamide, amlodipine)
Normalized name: indapamide / perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
Study: NCT00960544
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
Study: NCT01581684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for oral administration
Study: NCT01628913
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 400 mg bid p.o. (by mouth, twice daily)
Study: NCT01248793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
Study: NCT00638729
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inert tablet p.o., 60-90 min prior to estimated induction time
Study: NCT02580877
Drug: 67.5 mg oral insulin crystals daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: human insulin crystals in capsules
Study: NCT02580877
Drug: 500mg oral insulin crystals every other week
Approvals — FDA: no, EMA: no, PMDA: no
Description: human insulin crystals in capsules
Study: NCT00980148
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FDA approved, a 1 gm single dose, two 500 mg tablets.
Study: NCT00980148
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved, a 100 mg capsule twice a day for 7 days.
Study: NCT00052910
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00052910
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00940550
Drug: Prolonged-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tablet, once.
Study: NCT00940550
Drug: Placebo to match melatonin, zolpidem and temazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
Study: NCT02089932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02559635
Drug: Nestle Resource
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
Study: NCT03204760
Drug: Prednisolone Oral, Per 5 Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect of prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses in the treatment of mild to moderate acute asthma exacerbations in children.
Study: NCT03579758
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02663154
Drug: Saline inhaler
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
Study: NCT02665533
Drug: Diclofenac Sodium associated with Codeine
Normalized name: codeine / diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac Sodium 50 mg associated with Codeine 50 mg
Study: NCT03692403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01342731
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
Study: NCT01861847
Drug: 7-Keto Dehydroepiandrosterone
Normalized name: 7-keto-dehydroepiandrosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
Study: NCT01861847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
Study: NCT00003365
Drug: sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01469039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for IM injection, given monthly
Study: NCT00698828
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily subcutaneous injections of placebo for 12 weeks.
Study: NCT00698828
Drug: SUN11031 20 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.
Study: NCT00698828
Drug: SUN11031 40 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.
Study: NCT03165955
Drug: Oraxol
Normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
Study: NCT03346525
Drug: intramuscular benzathine penicillin G (BPG) prophylaxis
Normalized name: Penicillin G Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular BPG prophylaxis (600,000 IU for children \<30kg, 1.2 million IU for children ≥30kg), every 28 days.
Study: NCT02550444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
Study: NCT00537472
Drug: Low dose bupivicaine in spinal anesthetic
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 9 mg intrathecal single shot injection at start of surgery
Study: NCT02398526
Drug: Radium-223 dichloride, (Xofigo, BAY88-8223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage and treatment duration according to the decision of the treating physician
Study: NCT00041028
Drug: EF5
Normalized name: Hb 76(EF5), Met-thr
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00210847
Drug: tramadol, acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04686344
Drug: intermittent boluses of Hypertonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: intermittent boluses every 6 hours over 30 min for 48 hours